Patent: 10,261,091
✉ Email this page to a colleague
Summary for Patent: 10,261,091
| Title: | Humoral immune response against tumor antigens after treatment with a cancer antigen specific active immunotherapy and its association with improved clinical outcome |
| Abstract: | Compositions and methods are provided herein for predicting therapeutic outcome by measuring patient response to cellular antigen specific active immunotherapy (CASAI) using predetermined biomarkers. |
| Inventor(s): | GuhaThakurta; Debraj (Sammamish, WA), Trager; James (Seattle, WA), Sheikh; Nadeem (Seattle, WA) |
| Assignee: | Dendreon Corporation (Seattle, WA) |
| Application Number: | 14/479,084 |
| Patent Claims: | see list of patent claims |
Details for Patent 10,261,091
| Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
|---|---|---|---|---|---|---|---|
| Dendreon Pharmaceuticals Llc | PROVENGE | sipuleucel-t | Injection | 125197 | April 29, 2010 | ⤷ Start Trial | 2034-09-05 |
| >Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |
